



**DIASORIN S.P.A., THE ORDINARY SHAREHOLDERS' MEETING:**

- reviewed and approved the statutory financial statements at December 31, 2009 and a motion to distribute 11,000,000 euros in dividends;
- elected a new Board of Directors for the 2010, 2011 and 2012 reporting years;
- elected a new Board of Statutory Auditors and the Board's Chairman for the 2010, 2011 and 2012 reporting years;
- approved a new stock option plan;
- authorized the purchase and disposition of up to 750,000 common shares to be held as treasury shares and used in connection with the new incentive plan.

**Saluggia, April 27, 2010** – The Ordinary Shareholders' Meeting came to order today under the chairmanship of Gustavo Denegri, with shareholders representing 64.58% of the Company's share capital in attendance.

The Shareholders' Meeting reviewed and approved the statutory financial statements at December 31, 2009, which show revenues of 143.8 million euros, or 11.1% more than in 2008, and a net profit of 41.8 million euros, for a gain of 62.6% compared with 2008.

Concerning consolidated results, the Group recorded revenues of 304.1 million euros, for a gain of 24.3% compared with 2008, margins continuously improving, causing EBIT to rise by 49.0% to a total of 105.4 million euros (equal to 34.7% of revenues) and net profit of 70.0 million euros, for an increase of 87.0% compared with 2008.

The Shareholders' Meeting also approved a motion to distribute a dividend of 0.20 euros per common share, with a June 21, 2010 coupon record date and a June 24, 2010 payment date.

In addition, having first determined the number of Directors who will serve on the Board, the length of their term of office and their compensation, as required by the Bylaws, the Shareholders' Meeting elected Gustavo Denegri, Carlo Rosa, Antonio Boniolo, Chen Menachem Even, Michele Denegri, Enrico Amo, Franco Moschetti (independent), Giuseppe Alessandria (independent), Ezio Garibaldi (independent) and Gian Alberto Saporiti to serve on the Board of Directors for a term of office ending with the approval of the financial statements at December 31, 2012. The Shareholders' Meeting also elected a new Board of Statutory Auditors comprised of Bruno Marchina and Andrea Caretti, as Statutory Auditors, and Roberto Bracchetti, as Chairman. Both slates were filed by the shareholder IP S.r.l.. The candidates' *curricula*, accompanied by the related information, are available online at [www.Diasorin.com](http://www.Diasorin.com).

Moreover, pursuant to Article 114 *bis* of the Uniform Financial Code, the Shareholders' Meeting approved the establishment of a new stock option plan called the "DiaSorin S.p.A. 2010 Stock Option Plan," delegating to the Board of Directors the task of adopting the applicable Regulations. The Plan, which will have a duration of three years, calls for grants of up to 750,000 options, awarded free of charge to the Plan's beneficiaries. The characteristics of the "DiaSorin S.p.A. 2010 Stock Option Plan," including its terms and implementation requirements, are described in the Report of the Board of Directors and the Information Memorandum prepared in accordance with Article 84-bis of the Issuers' Regulations, which are available on the Company website.



Lastly, the Shareholders' Meeting took up and approved the motion to purchase and dispose of DiaSorin S.p.A. common shares. Pursuant to and for the purposes of Article 2357 of the Italian Civil Code, the Shareholders' Meeting authorized the Board of Directors, and the Chairman and the Chief Executive Officer acting on the Board's behalf, to purchase, in one or more installments and for a period of 18 months from the date of the Resolution approved by the Ordinary Shareholders' Meeting, up to 750,000 common shares, equal to 1.36% of the Company's share capital, for use in connection with the "DiaSorin S.p.A. 2010 Stock Option Plan."

At a meeting held after the Shareholders' Meeting had been adjourned, the Board of Directors reelected Gustavo Denegri as its Chairman and Antonio Boniolo as its Deputy Chairman, naming Carlo Rosa Chief Executive Officer and General Manager of the Company, providing them with the required powers of attorney.

The Board of Directors also appointed the following Committees:

Internal Control Committee

Ezio Garibaldi (Chairman), Franco Moscetti, Enrico Amo

Compensation Committee

Giuseppe Alessandria (Chairman), Ezio Garibaldi, Michele Denegri

Nominating Committee

Franco Moscetti (Chairman), Giuseppe Alessandria, Michele Denegri



The Diagnostic Specialist

---

### About DiaSorin

DiaSorin S.p.A., an international player in the market for in vitro diagnostics, develops, produces and markets reagent kits for clinical laboratory diagnostics. The DiaSorin Group is comprised of 22 companies based in Europe, the United States, Central and South America and Asia. It has more than 1,100 employees, including about 110 research and development specialists, and operates four manufacturing and research facilities in Saluggia (Vercelli, Italy), Dietzenbach (Germany), Stillwater (USA) and Dublin (Ireland). Thanks to its direct sales organization and an international network of over 80 independent distributors, the Group is present in more than 60 countries, offering a broad array of high quality products that includes comprehensive lines for each of the clinical segments in which it operates: infectious and viral diseases, management of bone and calcium related diseases, thyroid pathologies, oncology and fertility testing.

For additional information, please visit our website: [www.Diasorin.com](http://www.Diasorin.com)

---

### Contacts:

**Investor Relations Officer**

Laura Villa

**DiaSorin S.p.A.**

[laura.villa@diasorin.it](mailto:laura.villa@diasorin.it)

+39 0161487532

+39 348 15 11 542

**Press Office**

Carolina Mailander

[c.mailander@mailander.it](mailto:c.mailander@mailander.it)

+39 335 655 56 51

Bruno Caprioli

[caprioli@mailander.it](mailto:caprioli@mailander.it)

+39 335 590 14 02